PE20030830A1 - Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea - Google Patents

Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea

Info

Publication number
PE20030830A1
PE20030830A1 PE2003000187A PE2003000187A PE20030830A1 PE 20030830 A1 PE20030830 A1 PE 20030830A1 PE 2003000187 A PE2003000187 A PE 2003000187A PE 2003000187 A PE2003000187 A PE 2003000187A PE 20030830 A1 PE20030830 A1 PE 20030830A1
Authority
PE
Peru
Prior art keywords
ambroxol
pharyngeal
treatment
oral cavity
refers
Prior art date
Application number
PE2003000187A
Other languages
English (en)
Inventor
Anke Esperester
Uwe Pschorn
Jean-Michel Vix
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27740434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030830(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20030830A1 publication Critical patent/PE20030830A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A LA UTILIZACION DE AMBROXOL O UNA DE SUS SALES FARMACOLOGICAMENTE COMPATIBLES PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DOLOROSOS EN LA CAVIDAD BUCAL Y FARINGEA. SE REFIERE TAMBIEN A UNA COMPOSICION QUE CONTIENE 1)AMBROXOL O UNA DE SUS SALES FARMACOLOGICAMENTE COMPATIBLES; Y, 2)UNO O VARIOS PRINCIPIOS ACTIVOS SELECCIONADOS DE: ANTISEPTICOS, VITAMINAS, CORTICOIDES, ANTIFLOGISTICOS, ANTIBIOTICOS, ANTIMICOTICOS Y ENZIMAS PROTEOLITICAS, COMPOSICION QUE SE UTILIZA PARA LA PREPARACION DE UN MEDICAMENTO CON UN EFECTO ANALGESICO EN UN ESPACIO DE TIEMPO DE POR LO MENOS TRES HORAS DESPUES DE UNA APLICACION. SE REFIERE TAMBIEN A UNA FORMA DE ADMINISTRACION SEMI-SOLIDA EN FORMA DE GEL, CARACTERIZADA PORQUE LA DOSIS INDIVIDUAL ES DE 15 mg A 50 mg
PE2003000187A 2002-02-27 2003-02-26 Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea PE20030830A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208313A DE10208313A1 (de) 2002-02-27 2002-02-27 Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum

Publications (1)

Publication Number Publication Date
PE20030830A1 true PE20030830A1 (es) 2003-10-31

Family

ID=27740434

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000187A PE20030830A1 (es) 2002-02-27 2003-02-26 Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea

Country Status (21)

Country Link
EP (1) EP1480626A1 (es)
JP (1) JP2005518435A (es)
KR (1) KR20040084944A (es)
CN (1) CN1638749A (es)
AR (1) AR038698A1 (es)
AU (1) AU2003210345B2 (es)
BR (1) BR0308038A (es)
CA (1) CA2477105A1 (es)
DE (1) DE10208313A1 (es)
EC (1) ECSP045242A (es)
IS (1) IS7417A (es)
MX (1) MXPA04008220A (es)
MY (1) MY144781A (es)
PE (1) PE20030830A1 (es)
PL (1) PL371584A1 (es)
RU (1) RU2311176C2 (es)
TW (1) TW200306804A (es)
UA (1) UA86741C2 (es)
UY (1) UY27679A1 (es)
WO (1) WO2003072094A1 (es)
ZA (1) ZA200405635B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10332486A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung akuter Schmerzen
JP2005120063A (ja) * 2003-10-14 2005-05-12 Boehringer Ingelheim Pharma Gmbh & Co Kg 咽頭における炎症の治療のためのアンブロキソール
ITMI20032462A1 (it) * 2003-12-16 2005-06-17 Advance Holdings Ltd Metodo per preparare una caramella contenente ambroxolo e la caramella cosi' ottenuta
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
JP2007084471A (ja) * 2005-09-21 2007-04-05 Sunstar Inc 口腔用組成物および口腔用製品の選択方法
EP2015761A4 (en) * 2006-03-29 2009-07-29 Naveh Pharma 1996 Ltd METHODS AND COMPOSITION FOR THE TREATMENT OF THROAT SORE
JP5765934B2 (ja) * 2009-12-28 2015-08-19 サンスター株式会社 口腔用組成物
JP6171683B2 (ja) * 2012-08-03 2017-08-02 大正製薬株式会社 固形製剤
CN105769908B (zh) * 2016-05-06 2019-03-01 湖北凤凰白云山药业有限公司 一种化痰止咳的药物及其制备方法
WO2018089797A1 (en) 2016-11-14 2018-05-17 Mingwu Wang Formulations for the treatment of ocular surface diseases and related methods
CN106727621A (zh) * 2016-11-22 2017-05-31 郑州仁宏医药科技有限公司 一种治疗牙痛的西药散剂
JP6844394B2 (ja) * 2017-04-14 2021-03-17 大正製薬株式会社 固形組成物
EP3415143A1 (en) 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138020B1 (de) * 1983-09-17 1992-06-03 Dr. Karl Thomae GmbH Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat
DE3445226A1 (de) * 1983-12-14 1985-08-01 Reifenrath, Rainer Richard Otto, Dr.med., 7920 Heidenheim Pharmazeutisches erzeugnis zur behandlung und prophylaxe von infektionen sowie von husten und obstruktiven atemwegserkrankungen
US5122540A (en) * 1986-02-28 1992-06-16 W. Keith R. Watson Method and composition for treating warts and throat soreness with DMSO and citric acid
DE4415553A1 (de) * 1994-05-03 1995-11-09 Behringwerke Ag Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
WO1997041832A1 (fr) * 1996-05-02 1997-11-13 Taisho Pharmaceutical Co., Ltd. Suspension de medicament acide difficilement soluble dans l'eau
DE19933148A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物
DE20102817U1 (de) * 2000-02-23 2001-06-07 Bolder Arzneimittel GmbH, 50968 Köln Lutsch- und Kaupastillen mit Cyclodextrin
US6391886B1 (en) * 2000-12-04 2002-05-21 The Procter & Gamble Company Oral compositions having improved consumer aesthetics

Also Published As

Publication number Publication date
RU2311176C2 (ru) 2007-11-27
AU2003210345B2 (en) 2009-01-29
AR038698A1 (es) 2005-01-26
EP1480626A1 (de) 2004-12-01
JP2005518435A (ja) 2005-06-23
CA2477105A1 (en) 2003-09-04
MY144781A (en) 2011-11-15
TW200306804A (en) 2003-12-01
UY27679A1 (es) 2003-09-30
WO2003072094A1 (de) 2003-09-04
AU2003210345A1 (en) 2003-09-09
MXPA04008220A (es) 2004-11-26
PL371584A1 (en) 2005-06-27
RU2004129284A (ru) 2005-06-10
UA86741C2 (ru) 2009-05-25
CN1638749A (zh) 2005-07-13
DE10208313A1 (de) 2003-09-11
BR0308038A (pt) 2004-12-28
IS7417A (is) 2004-08-19
KR20040084944A (ko) 2004-10-06
ZA200405635B (en) 2005-05-31
ECSP045242A (es) 2004-09-28

Similar Documents

Publication Publication Date Title
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
ES2180251T3 (es) Comprimido revestido con polimero, que contiene amoxicilina y clavulanato.
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
NO20043723L (no) Farmasoytisk doseringform for avgivese gjennom slimhinner
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
UY25544A1 (es) Forma de dosificación de nefazodona
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AP2003002763A0 (en) Controlled release formulations for oral administration
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR0308305A (pt) Fórmulas dosadas de liberação controlada
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida

Legal Events

Date Code Title Description
FC Refusal